Advanced Filters
noise

carcinoma Clinical Trials

A listing of carcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 6,070 clinical trials

Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma

Nowadays, there are few second-line treatment options for advanced hepatocellular carcinoma (HCC). In order to further improve the efficacy of second-line treatment for advanced HCC, we plan to conduct a phase II clinical study to explore the efficacy and safety of the new second-line treatment for advanced HCC. As a …

18 years of age All Phase 2
W Wan-guang Zhang, M.D.

Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma

Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence. How to improve the prognosis of this group of patients is an urgent issue to be addressed.

18 - 75 years of age All Phase 4
Y Yanyan Jia

68Ga-PSMA PET in the Renal Cell Carcinoma

The primary research purpose is to evaluate the diagnostic efficacy of 68Ga-PSMA PET in metastatic lesions of locally advanced and advanced renal cell carcinoma, and to compare with that of enhanced CT. The second purpose is to evaluate whether 68Ga-PSMA PET can change the treatment decision of patients with locally …

18 - 90 years of age All Phase N/A
H Hai-Qiang Mai, MD,PhD

TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma

The NCCN guidelines recommend induction chemotherapy followed by concurrent chemoradiotherapy as the standard treatment for locoregionally advanced nasopharyngeal carcinoma (NPC). However, meta-analyses have shown significant survival differences between different induction chemotherapy regimens. How to choose an induction chemotherapy regimen and treatment course that ensures definitive therapeutic effects and low incidence …

18 - 65 years of age All Phase 2
S Site Public Contact

Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)

This is a study of oral nisin administration in patients with OSCC who are undergoing complete surgical resection surgery with or without adjuvant radiation/chemoradiation as part of their routine care at the University of California, San Francisco (UCSF).

18 years of age All Phase 1/2

Multifunctional Nutrition Tube in Dysphagia for Nasopharyngeal Carcinoma

This is a prospective multicenter study with patients with delayed dysphagia after radiotherapy for NPC. Patients enrolled are randomly divided equally into the observation group and the control group. All patients receive conventional care, and the observation group received IOE while the control group received NGT for enteral nutrition support. …

18 - 65 years of age All Phase N/A
Q Qunfang Zhou, MD

BAI-BACE for Advanced Lung Squamous Cell Carcinoma

Bronchial arterial infusion plus bronchial arterial chemoembolization (BAI-BACE) has been reported as non-first-line therapy to treat lung cancer in many hospitals in China. BAI, which uses chemotherapeutic drugs directly injected into the tumor and achieved a high concentration in a short time to kill the tumor. Then BACE could seal …

18 - 80 years of age All Phase N/A
M Mohamed BOUATTOUR, Dr

Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the most common liver primary cancer with a high rate of mortality. Since the results of IMbrave150, immunotherapy have emerged as a standard of care for HCC patients advanced and/or unresectable in first line of treatment. The objective response rate was about 30%, but half of …

18 years of age All Phase 2
H Hao Zhuang, M.D.

Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib

Currently, it has been demonstrated that CDK4 is highly expressed in hepatocellular carcinoma patients and is significantly associated with poor prognosis in hepatocellular carcinoma patients. Palbociclib is the world's first marketed inhibitor of the cell cycle protein-dependent kinase CDK4/6, which is capable of blocking cell cycle progression and inhibiting tumor …

18 - 75 years of age All Phase N/A
C Changzhen Shang, MD

Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma

This study aims to evaluate the efficacy and safety of donafenib as adjuvant therapy for postoperative patients with high-risk recurrent Hepatocellular Carcinoma. This is a multicenter, randomized controlled study.

18 - 75 years of age All Phase N/A

Simplify language using AI